Search Results : Cancer

1954 interactions found:

Sort by: Relevance Number of Pathways Number of Drugs Number of Diseases
Novel Symbols Name 1 Name 2
Pathways 1
Pathways 2
Drugs 1
Drugs 2
Diseases 1
Diseases 2
Novel
Novel
Symbols
FGFR1 and NRG1
Name 1
fibroblast growth factor receptor 1
Name2
neuregulin 1
Pathway 1
  • Signaling by activated point mutants of FGFR1
  • Signaling by FGFR1 in disease
  • Signaling by plasma membrane FGFR1 fusions
  • Epithelial-Mesenchymal Transition (EMT) during gastrulation
  • Formation of paraxial mesoderm
Pathway 2
  • Signaling by ERBB2
  • Signaling by ERBB4
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • PI3K events in ERBB4 signaling
  • SHC1 events in ERBB4 signaling
  • Nuclear signaling by ERBB4
  • PIP3 activates AKT signaling
  • GRB7 events in ERBB2 signaling
  • Downregulation of ERBB2:ERBB3 signaling
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • RAF/MAP kinase cascade
  • ERBB2 Regulates Cell Motility
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • ERBB2 Activates PTK6 Signaling
  • Downregulation of ERBB2 signaling
  • Long-term potentiation
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 TMD/JMD mutants
Drugs 1
  • Palifermin
  • Sorafenib
  • Heparin
  • 3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone
  • XL999
  • 3-(3-methoxybenzyl)-1H-pyrrolo[2,3-b]pyridine
  • (E)-[4-(3,5-Difluorophenyl)-3H-pyrrolo[2,3-b]pyridin-3-ylidene](3-methoxyphenyl)methanol
  • 3-[(3-(2-CARBOXYETHYL)-4-METHYLPYRROL-2-YL)METHYLENE]-2-INDOLINONE
  • Regorafenib
  • Ponatinib
  • Lenvatinib
  • Nintedanib
  • Tivozanib
  • Infigratinib
  • Fostamatinib
  • Erdafitinib
  • Pemigatinib
  • Futibatinib
  • Selpercatinib
  • Pralsetinib
Drugs 2
Diseases 1
  • Hypogonadotropic hypogonadism; Kallmann syndrome (KAL)
  • Craniosynostosis, including: Pfeiffer syndrome; Apert syndrome; Crouzon syndrome; Jackson-Weiss syndrome; Beare-Stevenson syndrome; Muenke craniosynostosis; Saethre-Chotzen syndrome; Craniosynostosis Boston type; Antley-Bixler syndrome; Carpenter syndrome; Craniofrontonasal dysplasia; Noonan syndrome; Baller-Gerold syndrome
  • Osteoglophonic dysplasia (OD); Osteoglophonic dwarfism (OGD)
  • Isolated orofacial clefts, including: Cleft lip with or without cleft palate; Cleft palate
Diseases 2
Novel
Novel
Symbols
CACNA1C and CD9
Name 1
calcium voltage-gated channel subunit alpha1 C
Name2
CD9 molecule
Pathway 1
  • Adrenaline,noradrenaline inhibits insulin secretion
  • NCAM1 interactions
  • Regulation of insulin secretion
  • Regulation of insulin secretion
  • Phase 0 - rapid depolarisation
  • Phase 2 - plateau phase
Pathway 2
  • Platelet degranulation
  • Acrosome Reaction and Sperm:Oocyte Membrane Binding
  • Uptake and function of diphtheria toxin
Drugs 1
  • Ergocalciferol
  • Enflurane
  • Ranolazine
  • Phenytoin
  • Isradipine
  • Topiramate
  • Ibutilide
  • Diltiazem
  • Amlodipine
  • Nimodipine
  • Nisoldipine
  • Spironolactone
  • Cinnarizine
  • Nicardipine
  • Nicardipine
  • Magnesium sulfate
  • Verapamil
  • Verapamil
  • Levomenthol
  • Ethanol
  • Felodipine
  • Nitrendipine
  • Nitrendipine
  • Miconazole
  • Nifedipine
  • Amiodarone
  • Calcium
  • Mibefradil
  • Dronedarone
  • Clevidipine
  • Nilvadipine
  • Nilvadipine
  • Drotaverine
  • Trimebutine
  • Barnidipine
  • Aranidipine
  • Benidipine
  • Cilnidipine
  • Efonidipine
  • Efonidipine
  • Efonidipine
  • Lacidipine
  • Levamlodipine
  • Manidipine
  • Butamben
  • Isavuconazole
  • Propiverine
  • Bioallethrin
  • Bioallethrin
  • Fish oil
Drugs 2
  • C31G
Diseases 1
  • Brugada syndrome (BRS)
  • Long QT syndrome, including: Romano-Ward syndrome; Jervell and Lange-Nielsen syndrome (JLNS)
Diseases 2
Novel
Novel
Symbols
CTNNB1 and ARHGEF4
Name 1
catenin beta 1
Name2
Rho guanine nucleotide exchange factor 4
Pathway 1
  • Degradation of beta-catenin by the destruction complex
  • Beta-catenin phosphorylation cascade
  • TCF dependent signaling in response to WNT
  • Formation of the beta-catenin:TCF transactivating complex
  • Formation of the beta-catenin:TCF transactivating complex
  • LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
  • Apoptotic cleavage of cell adhesion proteins
  • Deactivation of the beta-catenin transactivating complex
  • Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)
  • Ca2+ pathway
  • Adherens junctions interactions
  • Binding of TCF/LEF:CTNNB1 to target gene promoters
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • VEGFR2 mediated vascular permeability
  • Myogenesis
  • Myogenesis
  • Signaling by GSK3beta mutants
  • CTNNB1 S33 mutants aren't phosphorylated
  • CTNNB1 S37 mutants aren't phosphorylated
  • CTNNB1 S45 mutants aren't phosphorylated
  • CTNNB1 T41 mutants aren't phosphorylated
  • RHO GTPases activate IQGAPs
  • Transcriptional Regulation by VENTX
  • InlA-mediated entry of Listeria monocytogenes into host cells
  • RUNX3 regulates WNT signaling
  • Cardiogenesis
  • Germ layer formation at gastrulation
  • Regulation of CDH11 function
  • Regulation of CDH11 function
  • Regulation of CDH19 Expression and Function
  • Regulation of CDH1 Function
  • Degradation of CDH1
  • Regulation of CDH1 posttranslational processing and trafficking to plasma membrane
  • Formation of paraxial mesoderm
  • Formation of axial mesoderm
  • Formation of definitive endoderm
  • Somitogenesis
  • Regulation of MITF-M-dependent genes involved in pigmentation
  • Regulation of MITF-M-dependent genes involved in cell cycle and proliferation
  • Formation of the nephric duct
  • CDH11 homotypic and heterotypic interactions
  • Specification of the neural plate border
  • High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells
  • Transcriptional and post-translational regulation of MITF-M expression and activity
  • Regulation of PD-L1(CD274) transcription
Pathway 2
  • NRAGE signals death through JNK
  • G alpha (12/13) signalling events
  • RHOA GTPase cycle
  • CDC42 GTPase cycle
  • RAC1 GTPase cycle
Drugs 1
  • Urea
Drugs 2
Diseases 1
  • Pilomatricoma; Epithelioma calcificans of Malherbe
  • Gastric cancer
  • Hepatocellular carcinoma
  • Thyroid cancer
  • Colorectal cancer
  • Endometrial Cancer
Diseases 2
Novel
Novel
Symbols
CDK2 and CNNM1
Name 1
cyclin dependent kinase 2
Name2
cyclin and CBS domain divalent metal cation transport mediator 1
Pathway 1
  • G0 and Early G1
  • Telomere Extension By Telomerase
  • Activation of ATR in response to replication stress
  • Regulation of APC/C activators between G1/S and early anaphase
  • SCF(Skp2)-mediated degradation of p27/p21
  • Senescence-Associated Secretory Phenotype (SASP)
  • DNA Damage/Telomere Stress Induced Senescence
  • Processing of DNA double-strand break ends
  • TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest
  • Regulation of TP53 Activity through Phosphorylation
  • Regulation of TP53 Degradation
  • G2 Phase
  • Orc1 removal from chromatin
  • Activation of the pre-replicative complex
  • CDK-mediated phosphorylation and removal of Cdc6
  • Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes
  • Cyclin E associated events during G1/S transition
  • Cyclin D associated events in G1
  • Cyclin A/B1/B2 associated events during G2/M transition
  • p53-Dependent G1 DNA Damage Response
  • Cyclin A:Cdk2-associated events at S phase entry
  • PTK6 Regulates Cell Cycle
  • Meiotic recombination
  • Transcriptional regulation of granulopoiesis
  • Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)
  • Regulation of MITF-M-dependent genes involved in cell cycle and proliferation
  • Factors involved in megakaryocyte development and platelet production
Pathway 2
Drugs 1
  • 4-[5-(Trans-4-Aminocyclohexylamino)-3-Isopropylpyrazolo[1,5-a]Pyrimidin-7-Ylamino]-N,N-Dimethylbenzenesulfonamide
  • Staurosporine
  • Indirubin-3'-monoxime
  • 4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamine
  • Olomoucine
  • 4-[(4-Imidazo[1,2-a]Pyridin-3-Ylpyrimidin-2-Yl)Amino]Benzenesulfonamide
  • 2-Amino-6-Chloropyrazine
  • 6-O-Cyclohexylmethyl Guanine
  • N-[4-(2-Methylimidazo[1,2-a]Pyridin-3-Yl)-2-Pyrimidinyl]Acetamide
  • 1-Amino-6-Cyclohex-3-Enylmethyloxypurine
  • N-(5-Cyclopropyl-1h-Pyrazol-3-Yl)Benzamide
  • Purvalanol
  • [4-(2-Amino-4-Methyl-Thiazol-5-Yl)-Pyrimidin-2-Yl]-(3-Nitro-Phenyl)-Amine
  • (5R)-5-{[(2-Amino-3H-purin-6-yl)oxy]methyl}-2-pyrrolidinone
  • 4-(2,4-Dimethyl-1,3-thiazol-5-yl)-N-[4-(trifluoromethyl)phenyl]-2-pyrimidinamine
  • Hymenialdisine
  • (5-Chloropyrazolo[1,5-a]Pyrimidin-7-Yl)-(4-Methanesulfonylphenyl)Amine
  • 4-(5-Bromo-2-Oxo-2h-Indol-3-Ylazo)-Benzenesulfonamide
  • 4-(2,5-Dichloro-Thiophen-3-Yl)-Pyrimidin-2-Ylamine
  • 4-[(6-Amino-4-Pyrimidinyl)Amino]Benzenesulfonamide
  • 4-[3-Hydroxyanilino]-6,7-Dimethoxyquinazoline
  • SU9516
  • 3-Pyridin-4-Yl-2,4-Dihydro-Indeno[1,2-.C.]Pyrazole
  • Alvocidib
  • (2E,3S)-3-hydroxy-5'-[(4-hydroxypiperidin-1-yl)sulfonyl]-3-methyl-1,3-dihydro-2,3'-biindol-2'(1'H)-one
  • 1-[(2-Amino-6,9-Dihydro-1h-Purin-6-Yl)Oxy]-3-Methyl-2-Butanol
  • 4-((3r,4s,5r)-4-Amino-3,5-Dihydroxy-Hex-1-Ynyl)-5-Fluoro-3-[1-(3-Methoxy-1h-Pyrrol-2-Yl)-Meth-(Z)-Ylidene]-1,3-Dihydro-Indol-2-One
  • Lysine Nz-Carboxylic Acid
  • [2-Amino-6-(2,6-Difluoro-Benzoyl)-Imidazo[1,2-a]Pyridin-3-Yl]-Phenyl-Methanone
  • N'-[4-(2,4-Dimethyl-1,3-thiazol-5-yl)-2-pyrimidinyl]-N-hydroxyimidoformamide
  • N'-(Pyrrolidino[2,1-B]Isoindolin-4-On-8-Yl)-N-(Pyridin-2-Yl)Urea
  • 2-[Trans-(4-Aminocyclohexyl)Amino]-6-(Benzyl-Amino)-9-Cyclopentylpurine
  • 4-[4-(4-Methyl-2-Methylamino-Thiazol-5-Yl)-Pyrimidin-2-Ylamino]-Phenol
  • 3-[4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamino]-Phenol
  • PHENYLAMINOIMIDAZO(1,2-ALPHA)PYRIDINE
  • OLOMOUCINE II
  • TRIAZOLOPYRIMIDINE
  • Seliciclib
  • Bosutinib
  • 4-[(7-OXO-7H-THIAZOLO[5,4-E]INDOL-8-YLMETHYL)-AMINO]-N-PYRIDIN-2-YL-BENZENESULFONAMIDE
  • (13R,15S)-13-METHYL-16-OXA-8,9,12,22,24-PENTAAZAHEXACYCLO[15.6.2.16,9.1,12,15.0,2,7.0,21,25]HEPTACOSA-1(24),2,4,6,17(25),18,20-HEPTAENE-23,26-DIONE
  • N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(2-naphthyl)acetamide
  • 2-ANILINO-6-CYCLOHEXYLMETHOXYPURINE
  • 1-(5-OXO-2,3,5,9B-TETRAHYDRO-1H-PYRROLO[2,1-A]ISOINDOL-9-YL)-3-(5-PYRROLIDIN-2-YL-1H-PYRAZOL-3-YL)-UREA
  • (5-phenyl-7-(pyridin-3-ylmethylamino)pyrazolo[1,5-a]pyrimidin-3-yl)methanol
  • 2-(3,4-DIHYDROXYPHENYL)-8-(1,1-DIOXIDOISOTHIAZOLIDIN-2-YL)-3-HYDROXY-6-METHYL-4H-CHROMEN-4-ONE
  • (2R)-1-(DIMETHYLAMINO)-3-{4-[(6-{[2-FLUORO-5-(TRIFLUOROMETHYL)PHENYL]AMINO}PYRIMIDIN-4-YL)AMINO]PHENOXY}PROPAN-2-OL
  • 5-(2,3-dichlorophenyl)-N-(pyridin-4-ylmethyl)-3-thiocyanatopyrazolo[1,5-a]pyrimidin-7-amine
  • O6-CYCLOHEXYLMETHOXY-2-(4'-SULPHAMOYLANILINO) PURINE
  • (2S)-N-[(3E)-5-Cyclopropyl-3H-pyrazol-3-ylidene]-2-[4-(2-oxo-1-imidazolidinyl)phenyl]propanamide
  • 5-[(2-AMINOETHYL)AMINO]-6-FLUORO-3-(1H-PYRROL-2-YL)BENZO[CD]INDOL-2(1H)-ONE
  • N-cyclopropyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine
  • 3-((3-bromo-5-o-tolylpyrazolo[1,5-a]pyrimidin-7-ylamino)methyl)pyridine 1-oxide
  • 6-CYCLOHEXYLMETHOXY-2-(3'-CHLOROANILINO) PURINE
  • 3-bromo-5-phenyl-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
  • N-[5-(1,1-DIOXIDOISOTHIAZOLIDIN-2-YL)-1H-INDAZOL-3-YL]-2-(4-PIPERIDIN-1-YLPHENYL)ACETAMIDE
  • (3R)-3-(aminomethyl)-9-methoxy-1,2,3,4-tetrahydro-5H-[1]benzothieno[3,2-e][1,4]diazepin-5-one
  • 5-[5,6-BIS(METHYLOXY)-1H-BENZIMIDAZOL-1-YL]-3-{[1-(2-CHLOROPHENYL)ETHYL]OXY}-2-THIOPHENECARBOXAMIDE
  • 5-Bromoindirubin
  • (2S)-1-{4-[(4-Anilino-5-bromo-2-pyrimidinyl)amino]phenoxy}-3-(dimethylamino)-2-propanol
  • (2R)-1-{4-[(4-Anilino-5-bromo-2-pyrimidinyl)amino]phenoxy}-3-(dimethylamino)-2-propanol
  • (5E)-2-Amino-5-(2-pyridinylmethylene)-1,3-thiazol-4(5H)-one
  • 4-{5-[(Z)-(2,4-DIOXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZENESULFONAMIDE
  • 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]-2-FURYL}-N-METHYLBENZENESULFONAMIDE
  • 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZENESULFONAMIDE
  • 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}-2-(TRIFLUOROMETHYL)BENZENESULFONAMIDE
  • 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZOIC ACID
  • 4-{5-[(1Z)-1-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)ETHYL]-2-FURYL}BENZENESULFONAMIDE
  • N-[4-(2,4-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]-N',N'-DIMETHYL-BENZENE-1,4-DIAMINE
  • (5Z)-5-(3-BROMOCYCLOHEXA-2,5-DIEN-1-YLIDENE)-N-(PYRIDIN-4-YLMETHYL)-1,5-DIHYDROPYRAZOLO[1,5-A]PYRIMIDIN-7-AMINE
  • 6-(3,4-DIHYDROXYBENZYL)-3-ETHYL-1-(2,4,6-TRICHLOROPHENYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4(5H)-ONE
  • 6-(3-AMINOPHENYL)-N-(TERT-BUTYL)-2-(TRIFLUOROMETHYL)QUINAZOLIN-4-AMINE
  • 2-(4-(AMINOMETHYL)PIPERIDIN-1-YL)-N-(3_CYCLOHEXYL-4-OXO-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-5-YL)ACETAMIDE
  • 1-(3-(2,4-DIMETHYLTHIAZOL-5-YL)-4-OXO-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-5-YL)-3-(4-METHYLPIPERAZIN-1-YL)UREA
  • 4-{[5-(CYCLOHEXYLMETHOXY)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE
  • 4-{[5-(CYCLOHEXYLAMINO)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE
  • 4-({5-[(4-AMINOCYCLOHEXYL)AMINO][1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL}AMINO)BENZENESULFONAMIDE
  • 4-{[5-(CYCLOHEXYLOXY)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE
  • CAN-508
  • (2R)-1-[4-({4-[(2,5-Dichlorophenyl)amino]-2-pyrimidinyl}amino)phenoxy]-3-(dimethylamino)-2-propanol
  • (2S)-1-[4-({6-[(2,6-Difluorophenyl)amino]-4-pyrimidinyl}amino)phenoxy]-3-(dimethylamino)-2-propanol
  • (2S)-1-[4-({4-[(2,5-Dichlorophenyl)amino]-2-pyrimidinyl}amino)phenoxy]-3-(dimethylamino)-2-propanol
  • (2R)-1-[4-({6-[(2,6-Difluorophenyl)amino]-4-pyrimidinyl}amino)phenoxy]-3-(dimethylamino)-2-propanol
  • N-(2-METHOXYETHYL)-4-({4-[2-METHYL-1-(1-METHYLETHYL)-1H-IMIDAZOL-5-YL]PYRIMIDIN-2-YL}AMINO)BENZENESULFONAMIDE
  • 4-{[4-(1-CYCLOPROPYL-2-METHYL-1H-IMIDAZOL-5-YL)PYRIMIDIN-2-YL]AMINO}-N-METHYLBENZENESULFONAMIDE
  • 1-(3,5-DICHLOROPHENYL)-5-METHYL-1H-1,2,4-TRIAZOLE-3-CARBOXYLIC ACID
  • (2S)-1-(Dimethylamino)-3-(4-{[4-(2-methylimidazo[1,2-a]pyridin-3-yl)-2-pyrimidinyl]amino}phenoxy)-2-propanol
  • N-(4-{[(3S)-3-(dimethylamino)pyrrolidin-1-yl]carbonyl}phenyl)-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-amine
  • 2-{4-[4-({4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-yl}amino)phenyl]piperazin-1-yl}-2-oxoethanol
  • N-[3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRAZOL-4-YL]BENZAMIDE
  • RO-4584820
  • N-Methyl-4-{[(2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]amino}benzenesulfonamide
  • N-methyl-{4-[2-(7-oxo-6,7-dihydro-8H-[1,3]thiazolo[5,4-e]indol-8-ylidene)hydrazino]phenyl}methanesulfonamide
  • 3-{[(2,2-dioxido-1,3-dihydro-2-benzothien-5-yl)amino]methylene}-5-(1,3-oxazol-5-yl)-1,3-dihydro-2H-indol-2-one
  • 4-{[(2-Oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]amino}-N-(1,3-thiazol-2-yl)benzenesulfonamide
  • 3-{[4-([amino(imino)methyl]aminosulfonyl)anilino]methylene}-2-oxo-2,3-dihydro-1H-indole
  • 5-hydroxynaphthalene-1-sulfonamide
  • N-(4-sulfamoylphenyl)-1H-indazole-3-carboxamide
  • 4-[(6-chloropyrazin-2-yl)amino]benzenesulfonamide
  • N-phenyl-1H-pyrazole-3-carboxamide
  • 4-(acetylamino)-N-(4-fluorophenyl)-1H-pyrazole-3-carboxamide
  • (4E)-N-(4-fluorophenyl)-4-[(phenylcarbonyl)imino]-4H-pyrazole-3-carboxamide
  • {[(2,6-difluorophenyl)carbonyl]amino}-N-(4-fluorophenyl)-1H-pyrazole-3-carboxamide
  • 5-chloro-7-[(1-methylethyl)amino]pyrazolo[1,5-a]pyrimidine-3-carbonitrile
  • 5-[(4-AMINOCYCLOHEXYL)AMINO]-7-(PROPAN-2-YLAMINO)PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBONITRILE
  • 4-{[(2,6-difluorophenyl)carbonyl]amino}-N-[(3S)-piperidin-3-yl]-1H-pyrazole-3-carboxamide
  • AT-7519
  • 4-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine
  • 4-(4-propoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine
  • HYDROXY(OXO)(3-{[(2Z)-4-[3-(1H-1,2,4-TRIAZOL-1-YLMETHYL)PHENYL]PYRIMIDIN-2(5H)-YLIDENE]AMINO}PHENYL)AMMONIUM
  • 4-Methyl-5-[(2Z)-2-{[4-(4-morpholinyl)phenyl]imino}-2,5-dihydro-4-pyrimidinyl]-1,3-thiazol-2-amine
  • 6-CYCLOHEXYLMETHYLOXY-2-(4'-HYDROXYANILINO)PURINE
  • 4-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)--BENZAMIDE
  • 6-(CYCLOHEXYLMETHOXY)-8-ISOPROPYL-9H-PURIN-2-AMINE
  • 3-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)-BENZENESULFONAMIDE
  • (2R)-2-{[4-(benzylamino)-8-(1-methylethyl)pyrazolo[1,5-a][1,3,5]triazin-2-yl]amino}butan-1-ol
  • 3-({2-[(4-{[6-(CYCLOHEXYLMETHOXY)-9H-PURIN-2-YL]AMINO}PHENYL)SULFONYL]ETHYL}AMINO)PROPAN-1-OL
  • 6-CYCLOHEXYLMETHYLOXY-5-NITROSO-PYRIMIDINE-2,4-DIAMINE
  • 1-methyl-8-(phenylamino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxylic acid
  • 6-BROMO-13-THIA-2,4,8,12,19-PENTAAZATRICYCLO[12.3.1.1~3,7~]NONADECA-1(18),3(19),4,6,14,16-HEXAENE 13,13-DIOXIDE
  • (2R)-2-({9-(1-methylethyl)-6-[(4-pyridin-2-ylbenzyl)amino]-9H-purin-2-yl}amino)butan-1-ol
  • 1-[4-(AMINOSULFONYL)PHENYL]-1,6-DIHYDROPYRAZOLO[3,4-E]INDAZOLE-3-CARBOXAMIDE
  • 5-(2,3-dichlorophenyl)-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
  • 6-(2-fluorophenyl)-N-(pyridin-3-ylmethyl)imidazo[1,2-a]pyrazin-8-amine
  • 3-methyl-N-(pyridin-4-ylmethyl)imidazo[1,2-a]pyrazin-8-amine
  • 5-(2-fluorophenyl)-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
  • 3-bromo-5-phenyl-N-(pyridin-3-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
  • 3-bromo-5-phenyl-N-(pyrimidin-5-ylmethyl)pyrazolo[1,5-a]pyridin-7-amine
  • 3-bromo-6-phenyl-N-(pyrimidin-5-ylmethyl)imidazo[1,2-a]pyridin-8-amine
  • N-((2-aminopyrimidin-5-yl)methyl)-5-(2,6-difluorophenyl)-3-ethylpyrazolo[1,5-a]pyrimidin-7-amine
  • 3-cyclopropyl-5-phenyl-N-(pyridin-3-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
  • 4-{[4-AMINO-6-(CYCLOHEXYLMETHOXY)-5-NITROSOPYRIMIDIN-2-YL]AMINO}BENZAMIDE
  • 4-[(5-ISOPROPYL-1,3-THIAZOL-2-YL)AMINO]BENZENESULFONAMIDE
  • N-(5-Isopropyl-thiazol-2-YL)-2-pyridin-3-YL-acetamide
  • Variolin B
  • N(6)-dimethylallyladenine
  • Trilaciclib
Drugs 2
Diseases 1
Diseases 2
Novel
Novel
Symbols
ANXA5 and MAD1L1
Name 1
annexin A5
Name2
mitotic arrest deficient 1 like 1
Pathway 1
  • Platelet degranulation
Pathway 2
  • Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal
  • Separation of Sister Chromatids
  • Resolution of Sister Chromatid Cohesion
  • RHO GTPases Activate Formins
  • Mitotic Prometaphase
  • EML4 and NUDC in mitotic spindle formation
Drugs 1
  • Fluocinolone acetonide
  • L-Alpha-Glycerophosphorylserine
  • L-thioproline
  • K201 free base
  • sn-glycero-3-phosphoethanolamine
  • 1,4-Dideoxy-O2-Sulfo-Glucuronic Acid
  • N,O6-Disulfo-Glucosamine
  • 1,4-Dideoxy-5-Dehydro-O2-Sulfo-Glucuronic Acid
  • Copper
Drugs 2
Diseases 1
Diseases 2
Novel
Novel
Symbols
DAXX and GNL1
Name 1
death domain associated protein
Name2
G protein nucleolar 1 (putative)
Pathway 1
  • SUMOylation of transcription cofactors
  • Regulation of TP53 Degradation
  • HCMV Early Events
  • Inhibition of DNA recombination at telomere
  • Defective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations
  • Defective Inhibition of DNA Recombination at Telomere Due to ATRX Mutations
Pathway 2
Drugs 1
Drugs 2
Diseases 1
Diseases 2
Novel
Novel
Symbols
DAXX and NRG2
Name 1
death domain associated protein
Name2
neuregulin 2
Pathway 1
  • SUMOylation of transcription cofactors
  • Regulation of TP53 Degradation
  • HCMV Early Events
  • Inhibition of DNA recombination at telomere
  • Defective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations
  • Defective Inhibition of DNA Recombination at Telomere Due to ATRX Mutations
Pathway 2
  • Signaling by ERBB2
  • Signaling by ERBB4
  • Signaling by ERBB4
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • PI3K events in ERBB4 signaling
  • SHC1 events in ERBB4 signaling
  • Nuclear signaling by ERBB4
  • PIP3 activates AKT signaling
  • GRB7 events in ERBB2 signaling
  • Downregulation of ERBB2:ERBB3 signaling
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • RAF/MAP kinase cascade
  • ERBB2 Regulates Cell Motility
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • ERBB2 Activates PTK6 Signaling
  • Downregulation of ERBB2 signaling
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 TMD/JMD mutants
Drugs 1
Drugs 2
Diseases 1
Diseases 2
Novel
Novel
Symbols
IRS1 and TERT
Name 1
insulin receptor substrate 1
Name2
telomerase reverse transcriptase
Pathway 1
  • PI3K Cascade
  • IRS-mediated signalling
  • SOS-mediated signalling
  • SOS-mediated signalling
  • PIP3 activates AKT signaling
  • Interleukin-7 signaling
  • PI3K/AKT activation
  • PI3K/AKT activation
  • Signaling by ALK
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • IRS-related events triggered by IGF1R
  • Signaling by Leptin
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • IRS activation
  • Signal attenuation
  • Activated NTRK3 signals through PI3K
  • Signaling by ALK fusions and activated point mutants
  • Growth hormone receptor signaling
  • Signaling by LTK
Pathway 2
  • Telomere Extension By Telomerase
  • Formation of the beta-catenin:TCF transactivating complex
  • Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence
Drugs 1
  • [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID
Drugs 2
  • Zidovudine
  • Grn163l
  • Tertomotide
Diseases 1
Diseases 2
  • Cri du chat syndrome; Cat cry syndrome; Chromosme 5p deletion syndrome
Novel
Novel
Symbols
LOX and ZNF608
Name 1
lysyl oxidase
Name2
zinc finger protein 608
Pathway 1
  • Elastic fibre formation
  • Crosslinking of collagen fibrils
Pathway 2
Drugs 1
Drugs 2
Diseases 1
Diseases 2
Novel
Novel
Symbols
MAP3K8 and MTPAP
Name 1
mitogen-activated protein kinase kinase kinase 8
Name2
mitochondrial poly(A) polymerase
Pathway 1
  • CD28 dependent PI3K/Akt signaling
  • MAP3K8 (TPL2)-dependent MAPK1/3 activation
  • MAP3K8 (TPL2)-dependent MAPK1/3 activation
Pathway 2
  • Mitochondrial mRNA modification
Drugs 1
Drugs 2
Diseases 1
Diseases 2
Novel
Novel
Symbols
FLT1 and MIPEP
Name 1
fms related receptor tyrosine kinase 1
Name2
mitochondrial intermediate peptidase
Pathway 1
  • Neurophilin interactions with VEGF and VEGFR
  • VEGF binds to VEGFR leading to receptor dimerization
Pathway 2
Drugs 1
  • Sorafenib
  • Sunitinib
  • Vatalanib
  • TG-100801
  • OSI-930
  • Denibulin
  • Linifanib
  • IMC-1C11
  • Pazopanib
  • Axitinib
  • N-(4-chlorophenyl)-2-[(pyridin-4-ylmethyl)amino]benzamide
  • Regorafenib
  • Lenvatinib
  • Nintedanib
  • Polaprezinc
  • Foreskin fibroblast (neonatal)
  • Tivozanib
  • Fostamatinib
  • Selpercatinib
Drugs 2
Diseases 1
Diseases 2
Novel
Novel
Symbols
PKD1 and PPL
Name 1
polycystin 1, transient receptor potential channel interacting
Name2
periplakin
Pathway 1
  • VxPx cargo-targeting to cilium
  • VxPx cargo-targeting to cilium
Pathway 2
  • Formation of the cornified envelope
  • Butyrophilin (BTN) family interactions
Drugs 1
Drugs 2
Diseases 1
  • Polycystic kidney disease
Diseases 2
Novel
Novel
Symbols
CD27 and ELF1
Name 1
CD27 molecule
Name2
E74 like ETS transcription factor 1
Pathway 1
  • TNFs bind their physiological receptors
Pathway 2
  • RUNX1 regulates transcription of genes involved in BCR signaling
  • RUNX1 regulates transcription of genes involved in interleukin signaling
Drugs 1
Drugs 2
Diseases 1
Diseases 2
Novel
Novel
Symbols
CD27 and ETV6
Name 1
CD27 molecule
Name2
ETS variant transcription factor 6
Pathway 1
  • TNFs bind their physiological receptors
Pathway 2
  • Signaling by membrane-tethered fusions of PDGFRA or PDGFRB
  • Signaling by FLT3 fusion proteins
  • Signaling by FLT3 fusion proteins
Drugs 1
Drugs 2
Diseases 1
Diseases 2
  • Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia)
Novel
Novel
Symbols
KDR and SHOX2
Name 1
kinase insert domain receptor
Name2
SHOX homeobox 2
Pathway 1
  • Neurophilin interactions with VEGF and VEGFR
  • VEGF binds to VEGFR leading to receptor dimerization
  • Integrin cell surface interactions
  • VEGFA-VEGFR2 Pathway
  • VEGFA-VEGFR2 Pathway
  • VEGFR2 mediated cell proliferation
  • Signaling by membrane-tethered fusions of PDGFRA or PDGFRB
  • High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells
Pathway 2
Drugs 1
  • Sorafenib
  • Sunitinib
  • 1-{4-[4-Amino-6-(4-methoxyphenyl)furo[2,3-d]pyrimidin-5-yl]phenyl}-3-[2-fluoro-5-(trifluoromethyl)phenyl]urea
  • Cediranib
  • Vatalanib
  • XL999
  • TG-100801
  • XL820
  • CYC116
  • Ramucirumab
  • Pegdinetanib
  • RAF-265
  • Linifanib
  • IMC-1C11
  • Semaxanib
  • Pazopanib
  • Midostaurin
  • Axitinib
  • 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-3H-benzimidazol-5-yl]oxy]-N-methyl-pyridine-2-carboxamide
  • N-(4-phenoxyphenyl)-2-[(pyridin-4-ylmethyl)amino]nicotinamide
  • N-cyclopropyl-6-[(6,7-dimethoxyquinolin-4-yl)oxy]naphthalene-1-carboxamide
  • 6-chloro-N-pyrimidin-5-yl-3-{[3-(trifluoromethyl)phenyl]amino}-1,2-benzisoxazole-7-carboxamide
  • N-(CYCLOPROPYLMETHYL)-4-(METHYLOXY)-3-({5-[3-(3-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-YL}AMINO)BENZENESULFONAMIDE
  • N-[5-(ETHYLSULFONYL)-2-METHOXYPHENYL]-5-[3-(2-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-AMINE
  • 3-(2-aminoquinazolin-6-yl)-1-(3,3-dimethylindolin-6-yl)-4-methylpyridin-2(1H)-one
  • 3-(2-aminoquinazolin-6-yl)-4-methyl-1-[3-(trifluoromethyl)phenyl]pyridin-2(1H)-one
  • N'-(6-aminopyridin-3-yl)-N-(2-cyclopentylethyl)-4-methyl-benzene-1,3-dicarboxamide
  • N~4~-methyl-N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine
  • N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine
  • Cabozantinib
  • Regorafenib
  • Ponatinib
  • Lenvatinib
  • Nintedanib
  • Tivozanib
  • Fostamatinib
  • Erdafitinib
  • Foretinib
  • Ripretinib
  • Pralsetinib
  • Olinvacimab
Drugs 2
Diseases 1
Diseases 2
Novel
Novel
Symbols
AP2M1 and LPP
Name 1
adaptor related protein complex 2 subunit mu 1
Name2
LIM domain containing preferred translocation partner in lipoma
Pathway 1
  • Nef mediated downregulation of CD28 cell surface expression
  • Nef Mediated CD4 Down-regulation
  • Retrograde neurotrophin signalling
  • Retrograde neurotrophin signalling
  • Nef Mediated CD8 Down-regulation
  • Gap junction degradation
  • Formation of annular gap junctions
  • MHC class II antigen presentation
  • EPH-ephrin mediated repulsion of cells
  • Recycling pathway of L1
  • Recycling pathway of L1
  • WNT5A-dependent internalization of FZD4
  • WNT5A-dependent internalization of FZD2, FZD5 and ROR2
  • Cargo recognition for clathrin-mediated endocytosis
  • Clathrin-mediated endocytosis
  • VLDLR internalisation and degradation
  • LDL clearance
  • Potential therapeutics for SARS
Pathway 2
Drugs 1
Drugs 2
Diseases 1
Diseases 2
Novel
Novel
Symbols
DCTN1 and KRT5
Name 1
dynactin subunit 1
Name2
keratin 5
Pathway 1
  • MHC class II antigen presentation
  • HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand
  • XBP1(S) activates chaperone genes
  • COPI-mediated anterograde transport
  • COPI-independent Golgi-to-ER retrograde traffic
  • Signaling by ALK fusions and activated point mutants
Pathway 2
  • Type I hemidesmosome assembly
  • Keratinization
  • Formation of the cornified envelope
  • Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin
  • Developmental Lineage of Mammary Gland Luminal Epithelial Cells
  • Developmental Lineage of Mammary Gland Myoepithelial Cells
  • Developmental Lineage of Mammary Stem Cells
Drugs 1
Drugs 2
  • Zinc
  • Zinc acetate
Diseases 1
  • Perry syndrome
  • Amyotrophic lateral sclerosis (ALS); Lou Gehrig's disease
  • Distal hereditary motor neuropathies (dHMN)
Diseases 2
  • Epidermolysis bullosa simplex, including: Epidermolysis bullosa simplex, Dowling-Meara type (EBS-DM); Epidermolysis bullosa simplex, Koebner type (EBS-K); Epidermolysis bullosa simplex, Weber-Cockayne type (EBS-WC); Epidermolysis bullosa simplex with mottled pigmentation (EBS-MP); Epidermolysis bullosa simplex with migratory circinate erythema; Epidermolysis bullosa simplex, recessive; Epidermolysis bullosa, lethal acantholytic
  • Dowling-Degos disease
Novel
Novel
Symbols
MTOR and SLC45A1
Name 1
mechanistic target of rapamycin kinase
Name2
solute carrier family 45 member 1
Pathway 1
  • PIP3 activates AKT signaling
  • Macroautophagy
  • MTOR signalling
  • mTORC1-mediated signalling
  • HSF1-dependent transactivation
  • Energy dependent regulation of mTOR by LKB1-AMPK
  • CD28 dependent PI3K/Akt signaling
  • VEGFR2 mediated vascular permeability
  • TP53 Regulates Metabolic Genes
  • Constitutive Signaling by AKT1 E17K in Cancer
  • Regulation of TP53 Degradation
  • Regulation of PTEN gene transcription
  • Amino acids regulate mTORC1
  • High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells
Pathway 2
Drugs 1
  • Pimecrolimus
  • Sirolimus
  • Everolimus
  • Rimiducid
  • SF1126
  • XL765
  • Ridaforolimus
  • Temsirolimus
  • GSK-1059615
  • Fostamatinib
  • Oleandrin
Drugs 2
Diseases 1
Diseases 2
Novel
Novel
Symbols
NCOA1 and ZNF512
Name 1
nuclear receptor coactivator 1
Name2
zinc finger protein 512
Pathway 1
  • BMAL1:CLOCK,NPAS2 activates circadian expression
  • Recycling of bile acids and salts
  • Synthesis of bile acids and bile salts
  • Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol
  • Synthesis of bile acids and bile salts via 27-hydroxycholesterol
  • PPARA activates gene expression
  • PPARA activates gene expression
  • Endogenous sterols
  • Transcriptional activation of mitochondrial biogenesis
  • Activation of gene expression by SREBF (SREBP)
  • HATs acetylate histones
  • Transcriptional regulation of white adipocyte differentiation
  • Transcriptional regulation of white adipocyte differentiation
  • SUMOylation of transcription cofactors
  • Regulation of lipid metabolism by PPARalpha
  • Estrogen-dependent gene expression
  • NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux
  • NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis
  • Cytoprotection by HMOX1
  • Heme signaling
  • MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
  • MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
  • Transcriptional regulation of brown and beige adipocyte differentiation by EBF2
  • Expression of BMAL (ARNTL), CLOCK, and NPAS2
  • RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression
Pathway 2
Drugs 1
  • Genistein
  • Corticosterone
  • Prinaberel
  • ERB-196
  • (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID
  • [5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YL]ACETONITRILE
  • 2-(5-HYDROXY-NAPHTHALEN-1-YL)-1,3-BENZOOXAZOL-6-OL
  • TO-901317
  • 1-CHLORO-6-(4-HYDROXYPHENYL)-2-NAPHTHOL
  • 4-(4-HYDROXYPHENYL)-1-NAPHTHALDEHYDE OXIME
  • 5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-CARBONITRILE
  • GW-590735
  • 3-BROMO-6-HYDROXY-2-(4-HYDROXYPHENYL)-1H-INDEN-1-ONE
  • 3-(6-HYDROXY-NAPHTHALEN-2-YL)-BENZO[D]ISOOXAZOL-6-OL
  • (1R,3R)-5-[(2E)-3-{(1S,3R)-2,2,3-trimethyl-3-[6,6,6-trifluoro-5-hydroxy-5-(trifluoromethyl)hex-3-yn-1-yl]cyclopentyl}prop-2-en-1-ylidene]cyclohexane-1,3-diol
  • 3,20-Pregnanedione
  • Indeglitazar
  • (8alpha,10alpha,13alpha,17beta)-17-[(4-hydroxyphenyl)carbonyl]androsta-3,5-diene-3-carboxylic acid
  • Myristic acid
  • 1,3-CYCLOHEXANEDIOL, 4-METHYLENE-5-[(2E)-[(1S,3AS,7AS)-OCTAHYDRO-1-(5-HYDROXY-5-METHYL-1,3-HEXADIYNYL)-7A-METHYL-4H-INDEN-4-YLIDENE]ETHYLIDENE]-, (1R,3S,5Z)
  • Aleglitazar
Drugs 2
Diseases 1
Diseases 2
Novel
Novel
Symbols
CTNND2 and DNAH5
Name 1
catenin delta 2
Name2
dynein axonemal heavy chain 5
Pathway 1
Pathway 2
Drugs 1
Drugs 2
Diseases 1
  • Cri du chat syndrome; Cat cry syndrome; Chromosme 5p deletion syndrome
Diseases 2
Novel
Symbols
FGFR1 and NRG1
Name 1
fibroblast growth factor receptor 1
Name2
neuregulin 1
Pathway 1
  • Signaling by activated point mutants of FGFR1
  • Signaling by FGFR1 in disease
  • Signaling by plasma membrane FGFR1 fusions
  • Epithelial-Mesenchymal Transition (EMT) during gastrulation
  • Formation of paraxial mesoderm
Pathway 2
  • Signaling by ERBB2
  • Signaling by ERBB4
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • PI3K events in ERBB4 signaling
  • SHC1 events in ERBB4 signaling
  • Nuclear signaling by ERBB4
  • PIP3 activates AKT signaling
  • GRB7 events in ERBB2 signaling
  • Downregulation of ERBB2:ERBB3 signaling
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • RAF/MAP kinase cascade
  • ERBB2 Regulates Cell Motility
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • ERBB2 Activates PTK6 Signaling
  • Downregulation of ERBB2 signaling
  • Long-term potentiation
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 TMD/JMD mutants
Drugs 1
  • Palifermin
  • Sorafenib
  • Heparin
  • 3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone
  • XL999
  • 3-(3-methoxybenzyl)-1H-pyrrolo[2,3-b]pyridine
  • (E)-[4-(3,5-Difluorophenyl)-3H-pyrrolo[2,3-b]pyridin-3-ylidene](3-methoxyphenyl)methanol
  • 3-[(3-(2-CARBOXYETHYL)-4-METHYLPYRROL-2-YL)METHYLENE]-2-INDOLINONE
  • Regorafenib
  • Ponatinib
  • Lenvatinib
  • Nintedanib
  • Tivozanib
  • Infigratinib
  • Fostamatinib
  • Erdafitinib
  • Pemigatinib
  • Futibatinib
  • Selpercatinib
  • Pralsetinib
Drugs 2
Diseases 1
  • Hypogonadotropic hypogonadism; Kallmann syndrome (KAL)
  • Craniosynostosis, including: Pfeiffer syndrome; Apert syndrome; Crouzon syndrome; Jackson-Weiss syndrome; Beare-Stevenson syndrome; Muenke craniosynostosis; Saethre-Chotzen syndrome; Craniosynostosis Boston type; Antley-Bixler syndrome; Carpenter syndrome; Craniofrontonasal dysplasia; Noonan syndrome; Baller-Gerold syndrome
  • Osteoglophonic dysplasia (OD); Osteoglophonic dwarfism (OGD)
  • Isolated orofacial clefts, including: Cleft lip with or without cleft palate; Cleft palate
Diseases 2
Novel
Symbols
CACNA1C and CD9
Name 1
calcium voltage-gated channel subunit alpha1 C
Name2
CD9 molecule
Pathway 1
  • Adrenaline,noradrenaline inhibits insulin secretion
  • NCAM1 interactions
  • Regulation of insulin secretion
  • Regulation of insulin secretion
  • Phase 0 - rapid depolarisation
  • Phase 2 - plateau phase
Pathway 2
  • Platelet degranulation
  • Acrosome Reaction and Sperm:Oocyte Membrane Binding
  • Uptake and function of diphtheria toxin
Drugs 1
  • Ergocalciferol
  • Enflurane
  • Ranolazine
  • Phenytoin
  • Isradipine
  • Topiramate
  • Ibutilide
  • Diltiazem
  • Amlodipine
  • Nimodipine
  • Nisoldipine
  • Spironolactone
  • Cinnarizine
  • Nicardipine
  • Nicardipine
  • Magnesium sulfate
  • Verapamil
  • Verapamil
  • Levomenthol
  • Ethanol
  • Felodipine
  • Nitrendipine
  • Nitrendipine
  • Miconazole
  • Nifedipine
  • Amiodarone
  • Calcium
  • Mibefradil
  • Dronedarone
  • Clevidipine
  • Nilvadipine
  • Nilvadipine
  • Drotaverine
  • Trimebutine
  • Barnidipine
  • Aranidipine
  • Benidipine
  • Cilnidipine
  • Efonidipine
  • Efonidipine
  • Efonidipine
  • Lacidipine
  • Levamlodipine
  • Manidipine
  • Butamben
  • Isavuconazole
  • Propiverine
  • Bioallethrin
  • Bioallethrin
  • Fish oil
Drugs 2
  • C31G
Diseases 1
  • Brugada syndrome (BRS)
  • Long QT syndrome, including: Romano-Ward syndrome; Jervell and Lange-Nielsen syndrome (JLNS)
Diseases 2
Novel
Symbols
CTNNB1 and ARHGEF4
Name 1
catenin beta 1
Name2
Rho guanine nucleotide exchange factor 4
Pathway 1
  • Degradation of beta-catenin by the destruction complex
  • Beta-catenin phosphorylation cascade
  • TCF dependent signaling in response to WNT
  • Formation of the beta-catenin:TCF transactivating complex
  • Formation of the beta-catenin:TCF transactivating complex
  • LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
  • Apoptotic cleavage of cell adhesion proteins
  • Deactivation of the beta-catenin transactivating complex
  • Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)
  • Ca2+ pathway
  • Adherens junctions interactions
  • Binding of TCF/LEF:CTNNB1 to target gene promoters
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • VEGFR2 mediated vascular permeability
  • Myogenesis
  • Myogenesis
  • Signaling by GSK3beta mutants
  • CTNNB1 S33 mutants aren't phosphorylated
  • CTNNB1 S37 mutants aren't phosphorylated
  • CTNNB1 S45 mutants aren't phosphorylated
  • CTNNB1 T41 mutants aren't phosphorylated
  • RHO GTPases activate IQGAPs
  • Transcriptional Regulation by VENTX
  • InlA-mediated entry of Listeria monocytogenes into host cells
  • RUNX3 regulates WNT signaling
  • Cardiogenesis
  • Germ layer formation at gastrulation
  • Regulation of CDH11 function
  • Regulation of CDH11 function
  • Regulation of CDH19 Expression and Function
  • Regulation of CDH1 Function
  • Degradation of CDH1
  • Regulation of CDH1 posttranslational processing and trafficking to plasma membrane
  • Formation of paraxial mesoderm
  • Formation of axial mesoderm
  • Formation of definitive endoderm
  • Somitogenesis
  • Regulation of MITF-M-dependent genes involved in pigmentation
  • Regulation of MITF-M-dependent genes involved in cell cycle and proliferation
  • Formation of the nephric duct
  • CDH11 homotypic and heterotypic interactions
  • Specification of the neural plate border
  • High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells
  • Transcriptional and post-translational regulation of MITF-M expression and activity
  • Regulation of PD-L1(CD274) transcription
Pathway 2
  • NRAGE signals death through JNK
  • G alpha (12/13) signalling events
  • RHOA GTPase cycle
  • CDC42 GTPase cycle
  • RAC1 GTPase cycle
Drugs 1
  • Urea
Drugs 2
Diseases 1
  • Pilomatricoma; Epithelioma calcificans of Malherbe
  • Gastric cancer
  • Hepatocellular carcinoma
  • Thyroid cancer
  • Colorectal cancer
  • Endometrial Cancer
Diseases 2
Novel
Symbols
CDK2 and CNNM1
Name 1
cyclin dependent kinase 2
Name2
cyclin and CBS domain divalent metal cation transport mediator 1
Pathway 1
  • G0 and Early G1
  • Telomere Extension By Telomerase
  • Activation of ATR in response to replication stress
  • Regulation of APC/C activators between G1/S and early anaphase
  • SCF(Skp2)-mediated degradation of p27/p21
  • Senescence-Associated Secretory Phenotype (SASP)
  • DNA Damage/Telomere Stress Induced Senescence
  • Processing of DNA double-strand break ends
  • TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest
  • Regulation of TP53 Activity through Phosphorylation
  • Regulation of TP53 Degradation
  • G2 Phase
  • Orc1 removal from chromatin
  • Activation of the pre-replicative complex
  • CDK-mediated phosphorylation and removal of Cdc6
  • Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes
  • Cyclin E associated events during G1/S transition
  • Cyclin D associated events in G1
  • Cyclin A/B1/B2 associated events during G2/M transition
  • p53-Dependent G1 DNA Damage Response
  • Cyclin A:Cdk2-associated events at S phase entry
  • PTK6 Regulates Cell Cycle
  • Meiotic recombination
  • Transcriptional regulation of granulopoiesis
  • Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)
  • Regulation of MITF-M-dependent genes involved in cell cycle and proliferation
  • Factors involved in megakaryocyte development and platelet production
Pathway 2
Drugs 1
  • 4-[5-(Trans-4-Aminocyclohexylamino)-3-Isopropylpyrazolo[1,5-a]Pyrimidin-7-Ylamino]-N,N-Dimethylbenzenesulfonamide
  • Staurosporine
  • Indirubin-3'-monoxime
  • 4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamine
  • Olomoucine
  • 4-[(4-Imidazo[1,2-a]Pyridin-3-Ylpyrimidin-2-Yl)Amino]Benzenesulfonamide
  • 2-Amino-6-Chloropyrazine
  • 6-O-Cyclohexylmethyl Guanine
  • N-[4-(2-Methylimidazo[1,2-a]Pyridin-3-Yl)-2-Pyrimidinyl]Acetamide
  • 1-Amino-6-Cyclohex-3-Enylmethyloxypurine
  • N-(5-Cyclopropyl-1h-Pyrazol-3-Yl)Benzamide
  • Purvalanol
  • [4-(2-Amino-4-Methyl-Thiazol-5-Yl)-Pyrimidin-2-Yl]-(3-Nitro-Phenyl)-Amine
  • (5R)-5-{[(2-Amino-3H-purin-6-yl)oxy]methyl}-2-pyrrolidinone
  • 4-(2,4-Dimethyl-1,3-thiazol-5-yl)-N-[4-(trifluoromethyl)phenyl]-2-pyrimidinamine
  • Hymenialdisine
  • (5-Chloropyrazolo[1,5-a]Pyrimidin-7-Yl)-(4-Methanesulfonylphenyl)Amine
  • 4-(5-Bromo-2-Oxo-2h-Indol-3-Ylazo)-Benzenesulfonamide
  • 4-(2,5-Dichloro-Thiophen-3-Yl)-Pyrimidin-2-Ylamine
  • 4-[(6-Amino-4-Pyrimidinyl)Amino]Benzenesulfonamide
  • 4-[3-Hydroxyanilino]-6,7-Dimethoxyquinazoline
  • SU9516
  • 3-Pyridin-4-Yl-2,4-Dihydro-Indeno[1,2-.C.]Pyrazole
  • Alvocidib
  • (2E,3S)-3-hydroxy-5'-[(4-hydroxypiperidin-1-yl)sulfonyl]-3-methyl-1,3-dihydro-2,3'-biindol-2'(1'H)-one
  • 1-[(2-Amino-6,9-Dihydro-1h-Purin-6-Yl)Oxy]-3-Methyl-2-Butanol
  • 4-((3r,4s,5r)-4-Amino-3,5-Dihydroxy-Hex-1-Ynyl)-5-Fluoro-3-[1-(3-Methoxy-1h-Pyrrol-2-Yl)-Meth-(Z)-Ylidene]-1,3-Dihydro-Indol-2-One
  • Lysine Nz-Carboxylic Acid
  • [2-Amino-6-(2,6-Difluoro-Benzoyl)-Imidazo[1,2-a]Pyridin-3-Yl]-Phenyl-Methanone
  • N'-[4-(2,4-Dimethyl-1,3-thiazol-5-yl)-2-pyrimidinyl]-N-hydroxyimidoformamide
  • N'-(Pyrrolidino[2,1-B]Isoindolin-4-On-8-Yl)-N-(Pyridin-2-Yl)Urea
  • 2-[Trans-(4-Aminocyclohexyl)Amino]-6-(Benzyl-Amino)-9-Cyclopentylpurine
  • 4-[4-(4-Methyl-2-Methylamino-Thiazol-5-Yl)-Pyrimidin-2-Ylamino]-Phenol
  • 3-[4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamino]-Phenol
  • PHENYLAMINOIMIDAZO(1,2-ALPHA)PYRIDINE
  • OLOMOUCINE II
  • TRIAZOLOPYRIMIDINE
  • Seliciclib
  • Bosutinib
  • 4-[(7-OXO-7H-THIAZOLO[5,4-E]INDOL-8-YLMETHYL)-AMINO]-N-PYRIDIN-2-YL-BENZENESULFONAMIDE
  • (13R,15S)-13-METHYL-16-OXA-8,9,12,22,24-PENTAAZAHEXACYCLO[15.6.2.16,9.1,12,15.0,2,7.0,21,25]HEPTACOSA-1(24),2,4,6,17(25),18,20-HEPTAENE-23,26-DIONE
  • N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(2-naphthyl)acetamide
  • 2-ANILINO-6-CYCLOHEXYLMETHOXYPURINE
  • 1-(5-OXO-2,3,5,9B-TETRAHYDRO-1H-PYRROLO[2,1-A]ISOINDOL-9-YL)-3-(5-PYRROLIDIN-2-YL-1H-PYRAZOL-3-YL)-UREA
  • (5-phenyl-7-(pyridin-3-ylmethylamino)pyrazolo[1,5-a]pyrimidin-3-yl)methanol
  • 2-(3,4-DIHYDROXYPHENYL)-8-(1,1-DIOXIDOISOTHIAZOLIDIN-2-YL)-3-HYDROXY-6-METHYL-4H-CHROMEN-4-ONE
  • (2R)-1-(DIMETHYLAMINO)-3-{4-[(6-{[2-FLUORO-5-(TRIFLUOROMETHYL)PHENYL]AMINO}PYRIMIDIN-4-YL)AMINO]PHENOXY}PROPAN-2-OL
  • 5-(2,3-dichlorophenyl)-N-(pyridin-4-ylmethyl)-3-thiocyanatopyrazolo[1,5-a]pyrimidin-7-amine
  • O6-CYCLOHEXYLMETHOXY-2-(4'-SULPHAMOYLANILINO) PURINE
  • (2S)-N-[(3E)-5-Cyclopropyl-3H-pyrazol-3-ylidene]-2-[4-(2-oxo-1-imidazolidinyl)phenyl]propanamide
  • 5-[(2-AMINOETHYL)AMINO]-6-FLUORO-3-(1H-PYRROL-2-YL)BENZO[CD]INDOL-2(1H)-ONE
  • N-cyclopropyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine
  • 3-((3-bromo-5-o-tolylpyrazolo[1,5-a]pyrimidin-7-ylamino)methyl)pyridine 1-oxide
  • 6-CYCLOHEXYLMETHOXY-2-(3'-CHLOROANILINO) PURINE
  • 3-bromo-5-phenyl-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
  • N-[5-(1,1-DIOXIDOISOTHIAZOLIDIN-2-YL)-1H-INDAZOL-3-YL]-2-(4-PIPERIDIN-1-YLPHENYL)ACETAMIDE
  • (3R)-3-(aminomethyl)-9-methoxy-1,2,3,4-tetrahydro-5H-[1]benzothieno[3,2-e][1,4]diazepin-5-one
  • 5-[5,6-BIS(METHYLOXY)-1H-BENZIMIDAZOL-1-YL]-3-{[1-(2-CHLOROPHENYL)ETHYL]OXY}-2-THIOPHENECARBOXAMIDE
  • 5-Bromoindirubin
  • (2S)-1-{4-[(4-Anilino-5-bromo-2-pyrimidinyl)amino]phenoxy}-3-(dimethylamino)-2-propanol
  • (2R)-1-{4-[(4-Anilino-5-bromo-2-pyrimidinyl)amino]phenoxy}-3-(dimethylamino)-2-propanol
  • (5E)-2-Amino-5-(2-pyridinylmethylene)-1,3-thiazol-4(5H)-one
  • 4-{5-[(Z)-(2,4-DIOXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZENESULFONAMIDE
  • 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]-2-FURYL}-N-METHYLBENZENESULFONAMIDE
  • 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZENESULFONAMIDE
  • 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}-2-(TRIFLUOROMETHYL)BENZENESULFONAMIDE
  • 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZOIC ACID
  • 4-{5-[(1Z)-1-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)ETHYL]-2-FURYL}BENZENESULFONAMIDE
  • N-[4-(2,4-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]-N',N'-DIMETHYL-BENZENE-1,4-DIAMINE
  • (5Z)-5-(3-BROMOCYCLOHEXA-2,5-DIEN-1-YLIDENE)-N-(PYRIDIN-4-YLMETHYL)-1,5-DIHYDROPYRAZOLO[1,5-A]PYRIMIDIN-7-AMINE
  • 6-(3,4-DIHYDROXYBENZYL)-3-ETHYL-1-(2,4,6-TRICHLOROPHENYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4(5H)-ONE
  • 6-(3-AMINOPHENYL)-N-(TERT-BUTYL)-2-(TRIFLUOROMETHYL)QUINAZOLIN-4-AMINE
  • 2-(4-(AMINOMETHYL)PIPERIDIN-1-YL)-N-(3_CYCLOHEXYL-4-OXO-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-5-YL)ACETAMIDE
  • 1-(3-(2,4-DIMETHYLTHIAZOL-5-YL)-4-OXO-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-5-YL)-3-(4-METHYLPIPERAZIN-1-YL)UREA
  • 4-{[5-(CYCLOHEXYLMETHOXY)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE
  • 4-{[5-(CYCLOHEXYLAMINO)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE
  • 4-({5-[(4-AMINOCYCLOHEXYL)AMINO][1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL}AMINO)BENZENESULFONAMIDE
  • 4-{[5-(CYCLOHEXYLOXY)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE
  • CAN-508
  • (2R)-1-[4-({4-[(2,5-Dichlorophenyl)amino]-2-pyrimidinyl}amino)phenoxy]-3-(dimethylamino)-2-propanol
  • (2S)-1-[4-({6-[(2,6-Difluorophenyl)amino]-4-pyrimidinyl}amino)phenoxy]-3-(dimethylamino)-2-propanol
  • (2S)-1-[4-({4-[(2,5-Dichlorophenyl)amino]-2-pyrimidinyl}amino)phenoxy]-3-(dimethylamino)-2-propanol
  • (2R)-1-[4-({6-[(2,6-Difluorophenyl)amino]-4-pyrimidinyl}amino)phenoxy]-3-(dimethylamino)-2-propanol
  • N-(2-METHOXYETHYL)-4-({4-[2-METHYL-1-(1-METHYLETHYL)-1H-IMIDAZOL-5-YL]PYRIMIDIN-2-YL}AMINO)BENZENESULFONAMIDE
  • 4-{[4-(1-CYCLOPROPYL-2-METHYL-1H-IMIDAZOL-5-YL)PYRIMIDIN-2-YL]AMINO}-N-METHYLBENZENESULFONAMIDE
  • 1-(3,5-DICHLOROPHENYL)-5-METHYL-1H-1,2,4-TRIAZOLE-3-CARBOXYLIC ACID
  • (2S)-1-(Dimethylamino)-3-(4-{[4-(2-methylimidazo[1,2-a]pyridin-3-yl)-2-pyrimidinyl]amino}phenoxy)-2-propanol
  • N-(4-{[(3S)-3-(dimethylamino)pyrrolidin-1-yl]carbonyl}phenyl)-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-amine
  • 2-{4-[4-({4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-yl}amino)phenyl]piperazin-1-yl}-2-oxoethanol
  • N-[3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRAZOL-4-YL]BENZAMIDE
  • RO-4584820
  • N-Methyl-4-{[(2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]amino}benzenesulfonamide
  • N-methyl-{4-[2-(7-oxo-6,7-dihydro-8H-[1,3]thiazolo[5,4-e]indol-8-ylidene)hydrazino]phenyl}methanesulfonamide
  • 3-{[(2,2-dioxido-1,3-dihydro-2-benzothien-5-yl)amino]methylene}-5-(1,3-oxazol-5-yl)-1,3-dihydro-2H-indol-2-one
  • 4-{[(2-Oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]amino}-N-(1,3-thiazol-2-yl)benzenesulfonamide
  • 3-{[4-([amino(imino)methyl]aminosulfonyl)anilino]methylene}-2-oxo-2,3-dihydro-1H-indole
  • 5-hydroxynaphthalene-1-sulfonamide
  • N-(4-sulfamoylphenyl)-1H-indazole-3-carboxamide
  • 4-[(6-chloropyrazin-2-yl)amino]benzenesulfonamide
  • N-phenyl-1H-pyrazole-3-carboxamide
  • 4-(acetylamino)-N-(4-fluorophenyl)-1H-pyrazole-3-carboxamide
  • (4E)-N-(4-fluorophenyl)-4-[(phenylcarbonyl)imino]-4H-pyrazole-3-carboxamide
  • {[(2,6-difluorophenyl)carbonyl]amino}-N-(4-fluorophenyl)-1H-pyrazole-3-carboxamide
  • 5-chloro-7-[(1-methylethyl)amino]pyrazolo[1,5-a]pyrimidine-3-carbonitrile
  • 5-[(4-AMINOCYCLOHEXYL)AMINO]-7-(PROPAN-2-YLAMINO)PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBONITRILE
  • 4-{[(2,6-difluorophenyl)carbonyl]amino}-N-[(3S)-piperidin-3-yl]-1H-pyrazole-3-carboxamide
  • AT-7519
  • 4-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine
  • 4-(4-propoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine
  • HYDROXY(OXO)(3-{[(2Z)-4-[3-(1H-1,2,4-TRIAZOL-1-YLMETHYL)PHENYL]PYRIMIDIN-2(5H)-YLIDENE]AMINO}PHENYL)AMMONIUM
  • 4-Methyl-5-[(2Z)-2-{[4-(4-morpholinyl)phenyl]imino}-2,5-dihydro-4-pyrimidinyl]-1,3-thiazol-2-amine
  • 6-CYCLOHEXYLMETHYLOXY-2-(4'-HYDROXYANILINO)PURINE
  • 4-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)--BENZAMIDE
  • 6-(CYCLOHEXYLMETHOXY)-8-ISOPROPYL-9H-PURIN-2-AMINE
  • 3-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)-BENZENESULFONAMIDE
  • (2R)-2-{[4-(benzylamino)-8-(1-methylethyl)pyrazolo[1,5-a][1,3,5]triazin-2-yl]amino}butan-1-ol
  • 3-({2-[(4-{[6-(CYCLOHEXYLMETHOXY)-9H-PURIN-2-YL]AMINO}PHENYL)SULFONYL]ETHYL}AMINO)PROPAN-1-OL
  • 6-CYCLOHEXYLMETHYLOXY-5-NITROSO-PYRIMIDINE-2,4-DIAMINE
  • 1-methyl-8-(phenylamino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxylic acid
  • 6-BROMO-13-THIA-2,4,8,12,19-PENTAAZATRICYCLO[12.3.1.1~3,7~]NONADECA-1(18),3(19),4,6,14,16-HEXAENE 13,13-DIOXIDE
  • (2R)-2-({9-(1-methylethyl)-6-[(4-pyridin-2-ylbenzyl)amino]-9H-purin-2-yl}amino)butan-1-ol
  • 1-[4-(AMINOSULFONYL)PHENYL]-1,6-DIHYDROPYRAZOLO[3,4-E]INDAZOLE-3-CARBOXAMIDE
  • 5-(2,3-dichlorophenyl)-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
  • 6-(2-fluorophenyl)-N-(pyridin-3-ylmethyl)imidazo[1,2-a]pyrazin-8-amine
  • 3-methyl-N-(pyridin-4-ylmethyl)imidazo[1,2-a]pyrazin-8-amine
  • 5-(2-fluorophenyl)-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
  • 3-bromo-5-phenyl-N-(pyridin-3-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
  • 3-bromo-5-phenyl-N-(pyrimidin-5-ylmethyl)pyrazolo[1,5-a]pyridin-7-amine
  • 3-bromo-6-phenyl-N-(pyrimidin-5-ylmethyl)imidazo[1,2-a]pyridin-8-amine
  • N-((2-aminopyrimidin-5-yl)methyl)-5-(2,6-difluorophenyl)-3-ethylpyrazolo[1,5-a]pyrimidin-7-amine
  • 3-cyclopropyl-5-phenyl-N-(pyridin-3-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
  • 4-{[4-AMINO-6-(CYCLOHEXYLMETHOXY)-5-NITROSOPYRIMIDIN-2-YL]AMINO}BENZAMIDE
  • 4-[(5-ISOPROPYL-1,3-THIAZOL-2-YL)AMINO]BENZENESULFONAMIDE
  • N-(5-Isopropyl-thiazol-2-YL)-2-pyridin-3-YL-acetamide
  • Variolin B
  • N(6)-dimethylallyladenine
  • Trilaciclib
Drugs 2
Diseases 1
Diseases 2
Novel
Symbols
ANXA5 and MAD1L1
Name 1
annexin A5
Name2
mitotic arrest deficient 1 like 1
Pathway 1
  • Platelet degranulation
Pathway 2
  • Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal
  • Separation of Sister Chromatids
  • Resolution of Sister Chromatid Cohesion
  • RHO GTPases Activate Formins
  • Mitotic Prometaphase
  • EML4 and NUDC in mitotic spindle formation
Drugs 1
  • Fluocinolone acetonide
  • L-Alpha-Glycerophosphorylserine
  • L-thioproline
  • K201 free base
  • sn-glycero-3-phosphoethanolamine
  • 1,4-Dideoxy-O2-Sulfo-Glucuronic Acid
  • N,O6-Disulfo-Glucosamine
  • 1,4-Dideoxy-5-Dehydro-O2-Sulfo-Glucuronic Acid
  • Copper
Drugs 2
Diseases 1
Diseases 2
Novel
Symbols
DAXX and GNL1
Name 1
death domain associated protein
Name2
G protein nucleolar 1 (putative)
Pathway 1
  • SUMOylation of transcription cofactors
  • Regulation of TP53 Degradation
  • HCMV Early Events
  • Inhibition of DNA recombination at telomere
  • Defective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations
  • Defective Inhibition of DNA Recombination at Telomere Due to ATRX Mutations
Pathway 2
Drugs 1
Drugs 2
Diseases 1
Diseases 2
Novel
Symbols
DAXX and NRG2
Name 1
death domain associated protein
Name2
neuregulin 2
Pathway 1
  • SUMOylation of transcription cofactors
  • Regulation of TP53 Degradation
  • HCMV Early Events
  • Inhibition of DNA recombination at telomere
  • Defective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations
  • Defective Inhibition of DNA Recombination at Telomere Due to ATRX Mutations
Pathway 2
  • Signaling by ERBB2
  • Signaling by ERBB4
  • Signaling by ERBB4
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • PI3K events in ERBB4 signaling
  • SHC1 events in ERBB4 signaling
  • Nuclear signaling by ERBB4
  • PIP3 activates AKT signaling
  • GRB7 events in ERBB2 signaling
  • Downregulation of ERBB2:ERBB3 signaling
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • RAF/MAP kinase cascade
  • ERBB2 Regulates Cell Motility
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • ERBB2 Activates PTK6 Signaling
  • Downregulation of ERBB2 signaling
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 TMD/JMD mutants
Drugs 1
Drugs 2
Diseases 1
Diseases 2
Novel
Symbols
IRS1 and TERT
Name 1
insulin receptor substrate 1
Name2
telomerase reverse transcriptase
Pathway 1
  • PI3K Cascade
  • IRS-mediated signalling
  • SOS-mediated signalling
  • SOS-mediated signalling
  • PIP3 activates AKT signaling
  • Interleukin-7 signaling
  • PI3K/AKT activation
  • PI3K/AKT activation
  • Signaling by ALK
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • IRS-related events triggered by IGF1R
  • Signaling by Leptin
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • IRS activation
  • Signal attenuation
  • Activated NTRK3 signals through PI3K
  • Signaling by ALK fusions and activated point mutants
  • Growth hormone receptor signaling
  • Signaling by LTK
Pathway 2
  • Telomere Extension By Telomerase
  • Formation of the beta-catenin:TCF transactivating complex
  • Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence
Drugs 1
  • [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID
Drugs 2
  • Zidovudine
  • Grn163l
  • Tertomotide
Diseases 1
Diseases 2
  • Cri du chat syndrome; Cat cry syndrome; Chromosme 5p deletion syndrome
Novel
Symbols
LOX and ZNF608
Name 1
lysyl oxidase
Name2
zinc finger protein 608
Pathway 1
  • Elastic fibre formation
  • Crosslinking of collagen fibrils
Pathway 2
Drugs 1
Drugs 2
Diseases 1
Diseases 2
Novel
Symbols
MAP3K8 and MTPAP
Name 1
mitogen-activated protein kinase kinase kinase 8
Name2
mitochondrial poly(A) polymerase
Pathway 1
  • CD28 dependent PI3K/Akt signaling
  • MAP3K8 (TPL2)-dependent MAPK1/3 activation
  • MAP3K8 (TPL2)-dependent MAPK1/3 activation
Pathway 2
  • Mitochondrial mRNA modification
Drugs 1
Drugs 2
Diseases 1
Diseases 2
Novel
Symbols
FLT1 and MIPEP
Name 1
fms related receptor tyrosine kinase 1
Name2
mitochondrial intermediate peptidase
Pathway 1
  • Neurophilin interactions with VEGF and VEGFR
  • VEGF binds to VEGFR leading to receptor dimerization
Pathway 2
Drugs 1
  • Sorafenib
  • Sunitinib
  • Vatalanib
  • TG-100801
  • OSI-930
  • Denibulin
  • Linifanib
  • IMC-1C11
  • Pazopanib
  • Axitinib
  • N-(4-chlorophenyl)-2-[(pyridin-4-ylmethyl)amino]benzamide
  • Regorafenib
  • Lenvatinib
  • Nintedanib
  • Polaprezinc
  • Foreskin fibroblast (neonatal)
  • Tivozanib
  • Fostamatinib
  • Selpercatinib
Drugs 2
Diseases 1
Diseases 2
Novel
Symbols
PKD1 and PPL
Name 1
polycystin 1, transient receptor potential channel interacting
Name2
periplakin
Pathway 1
  • VxPx cargo-targeting to cilium
  • VxPx cargo-targeting to cilium
Pathway 2
  • Formation of the cornified envelope
  • Butyrophilin (BTN) family interactions
Drugs 1
Drugs 2
Diseases 1
  • Polycystic kidney disease
Diseases 2
Novel
Symbols
CD27 and ELF1
Name 1
CD27 molecule
Name2
E74 like ETS transcription factor 1
Pathway 1
  • TNFs bind their physiological receptors
Pathway 2
  • RUNX1 regulates transcription of genes involved in BCR signaling
  • RUNX1 regulates transcription of genes involved in interleukin signaling
Drugs 1
Drugs 2
Diseases 1
Diseases 2
Novel
Symbols
CD27 and ETV6
Name 1
CD27 molecule
Name2
ETS variant transcription factor 6
Pathway 1
  • TNFs bind their physiological receptors
Pathway 2
  • Signaling by membrane-tethered fusions of PDGFRA or PDGFRB
  • Signaling by FLT3 fusion proteins
  • Signaling by FLT3 fusion proteins
Drugs 1
Drugs 2
Diseases 1
Diseases 2
  • Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia)
Novel
Symbols
KDR and SHOX2
Name 1
kinase insert domain receptor
Name2
SHOX homeobox 2
Pathway 1
  • Neurophilin interactions with VEGF and VEGFR
  • VEGF binds to VEGFR leading to receptor dimerization
  • Integrin cell surface interactions
  • VEGFA-VEGFR2 Pathway
  • VEGFA-VEGFR2 Pathway
  • VEGFR2 mediated cell proliferation
  • Signaling by membrane-tethered fusions of PDGFRA or PDGFRB
  • High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells
Pathway 2
Drugs 1
  • Sorafenib
  • Sunitinib
  • 1-{4-[4-Amino-6-(4-methoxyphenyl)furo[2,3-d]pyrimidin-5-yl]phenyl}-3-[2-fluoro-5-(trifluoromethyl)phenyl]urea
  • Cediranib
  • Vatalanib
  • XL999
  • TG-100801
  • XL820
  • CYC116
  • Ramucirumab
  • Pegdinetanib
  • RAF-265
  • Linifanib
  • IMC-1C11
  • Semaxanib
  • Pazopanib
  • Midostaurin
  • Axitinib
  • 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-3H-benzimidazol-5-yl]oxy]-N-methyl-pyridine-2-carboxamide
  • N-(4-phenoxyphenyl)-2-[(pyridin-4-ylmethyl)amino]nicotinamide
  • N-cyclopropyl-6-[(6,7-dimethoxyquinolin-4-yl)oxy]naphthalene-1-carboxamide
  • 6-chloro-N-pyrimidin-5-yl-3-{[3-(trifluoromethyl)phenyl]amino}-1,2-benzisoxazole-7-carboxamide
  • N-(CYCLOPROPYLMETHYL)-4-(METHYLOXY)-3-({5-[3-(3-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-YL}AMINO)BENZENESULFONAMIDE
  • N-[5-(ETHYLSULFONYL)-2-METHOXYPHENYL]-5-[3-(2-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-AMINE
  • 3-(2-aminoquinazolin-6-yl)-1-(3,3-dimethylindolin-6-yl)-4-methylpyridin-2(1H)-one
  • 3-(2-aminoquinazolin-6-yl)-4-methyl-1-[3-(trifluoromethyl)phenyl]pyridin-2(1H)-one
  • N'-(6-aminopyridin-3-yl)-N-(2-cyclopentylethyl)-4-methyl-benzene-1,3-dicarboxamide
  • N~4~-methyl-N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine
  • N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine
  • Cabozantinib
  • Regorafenib
  • Ponatinib
  • Lenvatinib
  • Nintedanib
  • Tivozanib
  • Fostamatinib
  • Erdafitinib
  • Foretinib
  • Ripretinib
  • Pralsetinib
  • Olinvacimab
Drugs 2
Diseases 1
Diseases 2
Novel
Symbols
AP2M1 and LPP
Name 1
adaptor related protein complex 2 subunit mu 1
Name2
LIM domain containing preferred translocation partner in lipoma
Pathway 1
  • Nef mediated downregulation of CD28 cell surface expression
  • Nef Mediated CD4 Down-regulation
  • Retrograde neurotrophin signalling
  • Retrograde neurotrophin signalling
  • Nef Mediated CD8 Down-regulation
  • Gap junction degradation
  • Formation of annular gap junctions
  • MHC class II antigen presentation
  • EPH-ephrin mediated repulsion of cells
  • Recycling pathway of L1
  • Recycling pathway of L1
  • WNT5A-dependent internalization of FZD4
  • WNT5A-dependent internalization of FZD2, FZD5 and ROR2
  • Cargo recognition for clathrin-mediated endocytosis
  • Clathrin-mediated endocytosis
  • VLDLR internalisation and degradation
  • LDL clearance
  • Potential therapeutics for SARS
Pathway 2
Drugs 1
Drugs 2
Diseases 1
Diseases 2
Novel
Symbols
DCTN1 and KRT5
Name 1
dynactin subunit 1
Name2
keratin 5
Pathway 1
  • MHC class II antigen presentation
  • HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand
  • XBP1(S) activates chaperone genes
  • COPI-mediated anterograde transport
  • COPI-independent Golgi-to-ER retrograde traffic
  • Signaling by ALK fusions and activated point mutants
Pathway 2
  • Type I hemidesmosome assembly
  • Keratinization
  • Formation of the cornified envelope
  • Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin
  • Developmental Lineage of Mammary Gland Luminal Epithelial Cells
  • Developmental Lineage of Mammary Gland Myoepithelial Cells
  • Developmental Lineage of Mammary Stem Cells
Drugs 1
Drugs 2
  • Zinc
  • Zinc acetate
Diseases 1
  • Perry syndrome
  • Amyotrophic lateral sclerosis (ALS); Lou Gehrig's disease
  • Distal hereditary motor neuropathies (dHMN)
Diseases 2
  • Epidermolysis bullosa simplex, including: Epidermolysis bullosa simplex, Dowling-Meara type (EBS-DM); Epidermolysis bullosa simplex, Koebner type (EBS-K); Epidermolysis bullosa simplex, Weber-Cockayne type (EBS-WC); Epidermolysis bullosa simplex with mottled pigmentation (EBS-MP); Epidermolysis bullosa simplex with migratory circinate erythema; Epidermolysis bullosa simplex, recessive; Epidermolysis bullosa, lethal acantholytic
  • Dowling-Degos disease
Novel
Symbols
MTOR and SLC45A1
Name 1
mechanistic target of rapamycin kinase
Name2
solute carrier family 45 member 1
Pathway 1
  • PIP3 activates AKT signaling
  • Macroautophagy
  • MTOR signalling
  • mTORC1-mediated signalling
  • HSF1-dependent transactivation
  • Energy dependent regulation of mTOR by LKB1-AMPK
  • CD28 dependent PI3K/Akt signaling
  • VEGFR2 mediated vascular permeability
  • TP53 Regulates Metabolic Genes
  • Constitutive Signaling by AKT1 E17K in Cancer
  • Regulation of TP53 Degradation
  • Regulation of PTEN gene transcription
  • Amino acids regulate mTORC1
  • High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells
Pathway 2
Drugs 1
  • Pimecrolimus
  • Sirolimus
  • Everolimus
  • Rimiducid
  • SF1126
  • XL765
  • Ridaforolimus
  • Temsirolimus
  • GSK-1059615
  • Fostamatinib
  • Oleandrin
Drugs 2
Diseases 1
Diseases 2
Novel
Symbols
NCOA1 and ZNF512
Name 1
nuclear receptor coactivator 1
Name2
zinc finger protein 512
Pathway 1
  • BMAL1:CLOCK,NPAS2 activates circadian expression
  • Recycling of bile acids and salts
  • Synthesis of bile acids and bile salts
  • Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol
  • Synthesis of bile acids and bile salts via 27-hydroxycholesterol
  • PPARA activates gene expression
  • PPARA activates gene expression
  • Endogenous sterols
  • Transcriptional activation of mitochondrial biogenesis
  • Activation of gene expression by SREBF (SREBP)
  • HATs acetylate histones
  • Transcriptional regulation of white adipocyte differentiation
  • Transcriptional regulation of white adipocyte differentiation
  • SUMOylation of transcription cofactors
  • Regulation of lipid metabolism by PPARalpha
  • Estrogen-dependent gene expression
  • NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux
  • NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis
  • Cytoprotection by HMOX1
  • Heme signaling
  • MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
  • MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
  • Transcriptional regulation of brown and beige adipocyte differentiation by EBF2
  • Expression of BMAL (ARNTL), CLOCK, and NPAS2
  • RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression
Pathway 2
Drugs 1
  • Genistein
  • Corticosterone
  • Prinaberel
  • ERB-196
  • (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID
  • [5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YL]ACETONITRILE
  • 2-(5-HYDROXY-NAPHTHALEN-1-YL)-1,3-BENZOOXAZOL-6-OL
  • TO-901317
  • 1-CHLORO-6-(4-HYDROXYPHENYL)-2-NAPHTHOL
  • 4-(4-HYDROXYPHENYL)-1-NAPHTHALDEHYDE OXIME
  • 5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-CARBONITRILE
  • GW-590735
  • 3-BROMO-6-HYDROXY-2-(4-HYDROXYPHENYL)-1H-INDEN-1-ONE
  • 3-(6-HYDROXY-NAPHTHALEN-2-YL)-BENZO[D]ISOOXAZOL-6-OL
  • (1R,3R)-5-[(2E)-3-{(1S,3R)-2,2,3-trimethyl-3-[6,6,6-trifluoro-5-hydroxy-5-(trifluoromethyl)hex-3-yn-1-yl]cyclopentyl}prop-2-en-1-ylidene]cyclohexane-1,3-diol
  • 3,20-Pregnanedione
  • Indeglitazar
  • (8alpha,10alpha,13alpha,17beta)-17-[(4-hydroxyphenyl)carbonyl]androsta-3,5-diene-3-carboxylic acid
  • Myristic acid
  • 1,3-CYCLOHEXANEDIOL, 4-METHYLENE-5-[(2E)-[(1S,3AS,7AS)-OCTAHYDRO-1-(5-HYDROXY-5-METHYL-1,3-HEXADIYNYL)-7A-METHYL-4H-INDEN-4-YLIDENE]ETHYLIDENE]-, (1R,3S,5Z)
  • Aleglitazar
Drugs 2
Diseases 1
Diseases 2
Novel
Symbols
CTNND2 and DNAH5
Name 1
catenin delta 2
Name2
dynein axonemal heavy chain 5
Pathway 1
Pathway 2
Drugs 1
Drugs 2
Diseases 1
  • Cri du chat syndrome; Cat cry syndrome; Chromosme 5p deletion syndrome
Diseases 2

Page 1 out of 98 pages

© Madhavi K. Ganapathiraju 2012-2025